Rogers

Rogers

Yahoo Finance • 8 days ago

Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

F. Hoffmann-La Roche Ltd The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen. Most patients are diagnosed with m... Full story

Yahoo Finance • 9 days ago

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

F. Hoffmann-La Roche Ltd The cobas smart e immunoanalyser – the newest addition to Roche's industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre. With... Full story

Yahoo Finance • 10 days ago

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

F. Hoffmann-La Roche Ltd Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Kras... Full story

Yahoo Finance • 12 days ago

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

F. Hoffmann-La Roche Ltd Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient s... Full story

Yahoo Finance • 14 days ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

F. Hoffmann-La Roche Ltd Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales incr... Full story

Yahoo Finance • 15 days ago

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

F. Hoffmann-La Roche Ltd Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) F... Full story

Yahoo Finance • 17 days ago

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

F. Hoffmann-La Roche Ltd Phase III Krascendo 1 results demonstrated divarasib's superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer Patien... Full story

Yahoo Finance • 20 days ago

ASUS ProArt P16 & P14, Powered by NVIDIA RTX Spark, Now Available for Purchase in the United States

ASUS Computer International New ProArt laptops combine high-capacity unified memory, open agent and workflow ecosystems, and ASUS AI applications for private, customizable creation without token limits Fremont, CA, Oct. 16, 2026 (GLOBE N... Full story

Yahoo Finance • 20 days ago

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

F. Hoffmann-La Roche Ltd FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profi... Full story

Yahoo Finance • 23 days ago

Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-li... Full story

Yahoo Finance • 25 days ago

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

F. Hoffmann-La Roche Ltd In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2 UME is the leading cause of moderate and severe... Full story

Yahoo Finance • 27 days ago

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

F. Hoffmann-La Roche Ltd FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death... Full story

Yahoo Finance • 28 days ago

UBS's basket of expensive stocks faces derating risks

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig UBS equity strategists have constructed a 56-stock "expensive fundamentals" basket targeting companies with elevated valuations, below-average cash fl... Full story

Yahoo Finance • last month

Winners And Losers Of Q2: TTM Technologies (NASDAQ:TTMI) Vs The Rest Of The Electronic Components & Manufacturing Stocks

Winners And Losers Of Q2: TTM Technologies (NASDAQ:TTMI) Vs The Rest Of The Electronic Components & Manufacturing Stocks Looking back on electronic components & manufacturing stocks' Q2 earnings, we examine this quarter's best and worst p... Full story

Yahoo Finance • last month

Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine

F. Hoffmann-La Roche Ltd Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1 By targeting resis... Full story

Yahoo Finance • last month

Rogers (ROG) Shares Skyrocket, What You Need To Know

Rogers (ROG) Shares Skyrocket, What You Need To Know What Happened? Shares of engineered materials manufacturer Rogers (NYSE:ROG) jumped 17% in the morning session after it hosted an Investor Day, where management laid out strategy and m... Full story

Yahoo Finance • last month

Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Check out the companies making the biggest moves midday: Rogers — The maker of circuit materials surged 10% on better-than-expected earnings guidance. The company sees full-year earnings around $3.80 per share, excluding certain items, abo... Full story

Yahoo Finance • last month

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

F. Hoffmann-La Roche Ltd Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1 Fenebrutinib became the first investigational m... Full story

Yahoo Finance • last month

Rogers (ROG) Stock Looks Overvalued After Its 73% Rise

Rogers has delivered a sharp move over the past year, which puts today's valuation squarely in focus. With the share price well above where it started the period, the question now is how much of that climb is supported by the company's ear... Full story

Yahoo Finance • last month

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhi... Full story